Deutsche Bank analyst issues SELL recommendation for DC on September 22, 2026 06:37AM ET. The previous analyst recommendation was Sell.DC was trading at $6.34 at issue of the analyst recommendation.The overall analyst consensus : BUY.Current analyst recommendations are : 3 - Buy recommendations .Historical Analyst RecommendationsLatest 10 recommendationsReport DateAnalyst CompanyActionPrevious GradeNew GradePrice when posted 2026-09-22...
Key Points - Halper Sadeh LLC is investigating the sale of Priority Technology Holdings, Inc. to...
Key Points - Investors who purchased Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025...
Most sessions tell you nothing. These 6 moved Vaxart, Inc. (VXRT) enough to be worth explaining...
Every position is an argument with someone on the other side. Here is what the numbers...
from Lake Street issued a price target of $8.05 for PRTH on 2026-09-21 17:25:41.The adjusted price target was set to $8.05.At the time of the announcement, PRTH was trading at...
Robert Burns from H.C. Wainwright issued a price target of $27.00 for ACET on 2026-09-21 11:33:00.The adjusted price target was set to $27.00.At the time of the announcement, ACET was...
Anthony Joseph from Craig-Hallum issued a price target of $30.00 for AIP on 2026-09-21 11:17:11.The adjusted price target was set to $30.00.At the time of the announcement, AIP was trading...
Justin Crowley from Piper Sandler issued a price target of $9.50 for BCBP on 2026-09-21 10:49:09.The adjusted price target was set to $9.50.At the time of the announcement, BCBP was...
from Morgan Stanley issued a price target of $33.00 for VIA on 2026-09-21 00:59:36.The adjusted price target was set to $33.00.At the time of the announcement, VIA was trading at...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
